Skip to main content
Mirube

Sepsis - Monthly Reports

List of monthly reports on Sepsis

Sepsis Research Analysis

September 2026 sepsis research converged on precision diagnosis, biologically targeted organ protection, antimicrobial optimization, and infection-prevention implementation. Randomized evidence supported droplet digital PCR for substantially improved pathogen detection, while genomic epidemiology identified actionable environmental reservoirs of ESBL-producing Klebsiella pneumoniae in neonatal care. Mechanistic and translational studies highlighted endothelial glycocalyx injury, macrophage autop

Sepsis Research Analysis

Sepsis research in August 2026 continued a decisive shift from nonspecific syndrome-based management toward precision medicine guided by host biology, organ-specific mechanisms, and clinical phenotypes. Major therapeutic advances were predominantly preclinical, including macrophage-centered regulation through TG2-vimentin and PARP7-TBK1 pathways, as well as epigenetic control of kidney injury through the DDX3x-histone lactylation-NINJ1 axis. Diagnostic development progressed through rapid direct

Sepsis Research Analysis

July 2026 sepsis research showed a sustained transition from nonspecific anti-inflammatory treatment toward precision, mechanism-based, and organ-specific interventions. Major therapeutic directions included immunometabolic regulation, ferroptosis and inflammasome control, targeted mediator clearance, neuroimmune modulation, and biomarker-guided host-response therapy. Diagnostic research advanced through rapid molecular pathogen detection, multiplex droplet digital PCR, multiomic profiling, and

Sepsis Research Analysis

June’s sepsis research converged on targetable host-response biology while delivering practice-changing randomized evidence. Mechanistic papers prioritized endoplasmic reticulum stress nodes (IκBζ–XBP1s/Regnase‑1 and DAPK2–HSPA5–IRE1α) as drivers of hyperinflammation, rising to the top after score normalization with recency weighting. Large adaptive and multicenter RCTs supported safer definitive beta‑lactam choices for MSSA/PSSA bacteremia and individualized shorter antibiotic courses in cultur

Sepsis Research Analysis

May’s sepsis research converged on host-directed immunometabolism, rapid resistance diagnostics, and actionable drug targets. Mechanistic studies nominated PLA2G5 as a circulating hemolytic driver, and revealed AIM2-driven PANoptosis as an itaconate-modulated node, while NLRP3 inhibition was enabled via repurposed ciclopirox. Kidney-protective metabolic control through the GATM–PDK4 axis suggests tractable organ-specific therapy. Machine learning from routine antibiograms (MALCA) delivered same-

Sepsis Research Analysis

April’s sepsis research converged on host-directed mechanisms and rigorous clinical testing. Mechanistic advances included a conserved enhancer controlling B cell IL-10, a neutrophil migratory checkpoint (RPSA–OLFM4) with human validation, and two complementary NLRP3 strategies: an LRR-binding inhibitor (LOC14) that overcomes MCC950 resistance and a dual-target approach (roburic acid nanoparticles) coordinating inflammasome and redox control. Clinically, a large pragmatic NEJM trial found no kid

Sepsis Research Analysis

March 2026 sepsis research converged on deployable precision care and host-directed immunomodulation. A large phase 3 RCT showed that procalcitonin-guided ED assessment reduced 28-day mortality, while a prospective 1-hour IL-6/sTNFR1 plus bicarbonate panel operationalized bedside ARDS subphenotyping. A validated three-biomarker ML score (PCT, sTREM-1, IL-6) quantified immune dysregulation and identified hydrocortisone-responsive patients. Mechanistic studies nominated druggable host pathways—STA

Sepsis Research Analysis

February’s sepsis research converged on host-directed immunomodulation and pragmatic implementation. A large cluster RCT in Nature Medicine showed that a digitally enabled stewardship program markedly reduced antibiotics for respiratory infections without increasing sepsis-related hospitalizations. Mechanistic advances identified a BDNF-derived peptide (BDP-12) that antagonizes TLR4 to blunt lung inflammation and an FGF13–ERK/HIF-1α glycolytic axis that is therapeutically tractable. Neuroepigene

Sepsis Research Analysis

January’s sepsis research converged on host-centered mechanisms, precision adjuncts, and rapid diagnostics, with recency-weighted normalization highlighting late-month mechanistic breakthroughs. Platelet-derived PITT structures and neutrophil EGFR–PGLYRP1–TREM-1 signaling emerged as druggable thrombo-inflammatory axes. A Nature study reframed outcomes through disease tolerance and aging, while multi-omic risk enrichment (BEYOND) demonstrated a clinically meaningful adjunctive benefit in a random

Sepsis Research Analysis

December sepsis research increasingly treated sepsis as a dynamic, anatomically heterogeneous syndrome requiring longitudinal molecular profiling and phenotype-specific intervention. Major mechanistic themes included mitochondrial dysfunction, endothelial injury, ferroptosis, PANoptosis, immunothrombosis, cardiac endothelial senescence, and organ-specific immune reprogramming. Translational research expanded from biomarker discovery toward targeted strategies, including Notch1-DLL4 blockade, IFN

Sepsis Research Analysis

November 2025 sepsis research showed a clear shift toward precision diagnosis, biologically informed treatment stratification, and scalable implementation. Mechanistic studies identified new host-directed targets involving endothelial ALOX15, the Nur77–thrombomodulin pathway, immunometabolic PKM2 signaling, and gut–liver NETosis, while large clinical studies demonstrated that bundled care and structured neonatal examination can reduce infection-related harm and antibiotic exposure. Rapid host tr

Sepsis Research Analysis

October 2025 sepsis research increasingly emphasized precision management supported by bedside physiology, immune endotyping, and rapid molecular diagnostics. The strongest clinical signal came from the ANDROMEDA-SHOCK-2 randomized trial, in which capillary-refill-time-guided resuscitation improved a hierarchical patient-centered outcome, primarily by reducing organ-support duration. Complementary evidence supported selected adjunctive hemodynamic strategies, including ultrashort-acting beta-blo

Sepsis Research Analysis

September 2025 sepsis research showed a strong shift toward mechanistically defined, targetable pathways spanning immune collapse, pyroptosis, NETosis, endothelial inflammation, and organ-specific injury. Preclinical studies identified several actionable interventions, including gasdermin D pore blockade, FPR1 inhibition, and IGFBP6 pathway modulation, with survival or organ-protection benefits in animal models. In parallel, label-efficient EHR phenotyping and other rapid diagnostic approaches a

Sepsis Research Analysis

August 2025 sepsis research converged on three major directions: faster pathogen and host-response diagnostics, biomarker-guided immunomodulation, and mechanistically targeted prevention of organ dysfunction. Metagenomic sequencing, rapid molecular assays, multiplex host-response panels, and machine-learning tools increasingly aim to shorten time to actionable antimicrobial decisions, while externally validated beta-lactam dosing nomograms address pharmacokinetic variability during renal replace

Sepsis Research Analysis

July 2025 sepsis research showed a strong shift toward host-directed, mechanism-based intervention, particularly across immunometabolism, immunothrombosis, ferroptosis, pyroptosis, and neuroimmune signaling. Rapid and minimally invasive diagnosis also advanced through hyperspectral imaging, extracellular-vesicle proteomics, direct molecular pathogen detection, and AI-enabled sensor platforms. Several studies provided translationally relevant therapeutic signals, including factor XI inhibition, t

Sepsis Research Analysis

June 2025 sepsis research showed a clear shift toward precision immunology, endothelial and organ-specific mechanisms, and implementation-ready diagnostics. Mechanistic studies identified actionable inflammatory circuits, including PGK1-NLRP3, endothelial CLEC5A, TNF-caspase-8 pyroptosis, and lactylation of HADHA in septic cardiomyopathy. Large human cohorts and multi-cohort transcriptomic analyses advanced pathogen-informed classification, immune endotyping, and prognostic biomarkers such as th

Sepsis Research Analysis

May 2025 sepsis research showed a strong shift toward precision, mechanism-informed care, combining high-quality clinical trials with deployable diagnostics and host-directed therapeutic discovery. Hemodynamic management was directly challenged by the OPTPRESS randomized trial, which demonstrated harm from higher MAP targets in older patients with septic shock, while the A2B trial refined sedation practice by supporting propofol over alpha-2 agonists for ventilated ICU patients. Translational st

Sepsis Research Analysis

April 2025 sepsis research showed a strong convergence of precision phenotyping, antibiotic stewardship, host-directed therapy, and pathogen surveillance. The most practice-ready evidence came from randomized trials supporting shorter antibiotic courses in selected neonatal sepsis and biomarker-guided antibiotic discontinuation, while mechanistic studies identified new therapeutic opportunities involving pyroptosis, host antimicrobial defense, and immune suppression. Organ-origin plasma proteomi

Sepsis Research Analysis

March 2025 sepsis research converged on precision host biology, rapid diagnostics, immune-endothelial injury, and pragmatic infection prevention. Mechanistic studies identified endothelial ferroptosis, TLR4/redox-driven microbiome disruption, and phase-specific immune dysfunction as actionable pathways, while AI-based vasopressor optimization offered a clinically testable approach to septic shock management. Large clinical and global-health studies supported scalable prevention strategies, inclu

Sepsis Research Analysis

February 2025 sepsis research showed a strong convergence of mechanistic immunology, rapid diagnostics, predictive analytics, and evidence-based reassessment of clinical policy. Translational studies identified actionable pathways including fucosylated haptoglobin–Mincle signaling, endothelial GSDMD-mediated vascular injury, and S100A8/A9–RAGE–Drp1-driven muscle mitochondrial fragmentation. Diagnostic development accelerated through plasma cell-free DNA metagenomics, droplet digital PCR, and lon

Sepsis Research Analysis

January 2025 sepsis research advanced along three connected fronts: mechanistic definition of microbiota–pathogen–host interactions, precision characterization of immune dysfunction, and clinically actionable diagnostics and treatment optimization. Preclinical studies identified the AhR–enterobactin axis, pathogen-derived carbon dots, and neutrophil subpopulations as important determinants of inflammatory injury and immunosuppression. Diagnostic development accelerated through ddPCR, host transc